Payment overview · 2025
General Payments
$363.49
18 reported records · 11 companies
Healthcare provider profile · identity verified
David Lee Adams, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HIXSON, TN · NPI 1467463299
Verified facts
What the public records show
CMS Open Payments records show David Lee Adams, M.D. received $363.49 in general payments during 2025 across 18 reported records.
Abbott Laboratories accounted for 25.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 285 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $94.19 | 25.9% | 4 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $42.94 | 11.8% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$41.90 | 11.5% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $31.81 | 8.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.66 | 8.4% | 2 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.64 | 7.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $22.05 | 6.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.39 | 5.9% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $20.78 | 5.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.17 | 4.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.96 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $363.49 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $94.19 | 4 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $42.94 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $31.81 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $30.66 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $30.66 | 2 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $25.64 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $22.31 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $21.39 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
115 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
285 | 67 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 762 | 253 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 664 | 223 |
| Levothyroxine Sodium | Levothyroxine Sodium | 649 | 203 |
| Amlodipine Besylate | Amlodipine Besylate | 636 | 223 |
| Lisinopril | Lisinopril | 556 | 193 |
| Tamsulosin Hcl | Tamsulosin Hcl | 357 | 121 |
| Omeprazole | Omeprazole | 343 | 111 |
| Losartan Potassium | Losartan Potassium | 323 | 110 |
| Sertraline Hcl | Sertraline Hcl | 306 | 100 |
| Metformin Hcl Er | Metformin Hcl | 294 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 294 | 110 |
| Gabapentin | Gabapentin | 287 | 106 |
| Eliquis | Apixaban | 285 | 67 |
| Carvedilol | Carvedilol | 249 | 92 |
| Trazodone Hcl | Trazodone Hcl | 240 | 85 |
| Metformin Hcl | Metformin Hcl | 234 | 86 |
| Duloxetine Hcl | Duloxetine Hcl | 230 | 80 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 217 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 213 | 78 |
| Simvastatin | Simvastatin | 198 | 68 |
| Meloxicam | Meloxicam | 195 | 79 |
| Montelukast Sodium | Montelukast Sodium | 186 | 65 |
| Pravastatin Sodium | Pravastatin Sodium | 158 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 140 | 64 |
| Potassium Chloride | Potassium Chloride | 140 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 57 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 124 | 44 |
| Allopurinol | Allopurinol | 122 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 45 |
| Ozempic | Semaglutide | 115 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 111 | 25 |
| Bupropion Xl | Bupropion Hcl | 109 | 35 |
| Famotidine | Famotidine | 109 | 44 |
| Mirtazapine | Mirtazapine | 109 | 43 |
| Tramadol Hcl | Tramadol Hcl | 103 | 31 |
| Spironolactone | Spironolactone | 89 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 86 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 85 | 28 |
| Jardiance | Empagliflozin | 85 | 27 |
| Furosemide | Furosemide | 82 | 36 |
| Alprazolam | Alprazolam | 80 | 20 |
| Lorazepam | Lorazepam | 80 | 13 |
| Finasteride | Finasteride | 79 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 24 |
| Prednisone | Prednisone | 78 | 54 |
| Celecoxib | Celecoxib | 75 | 33 |
| Ramipril | Ramipril | 75 | 23 |
| Buspirone Hcl | Buspirone Hcl | 74 | 27 |
| Synthroid | Levothyroxine Sodium | 73 | 22 |
| Chlorthalidone | Chlorthalidone | 70 | 23 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 69 | 25 |
| Trulicity | Dulaglutide | 68 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 23 |
| Ezetimibe | Ezetimibe | 65 | 28 |
| Alendronate Sodium | Alendronate Sodium | 64 | 21 |
| Pregabalin | Pregabalin | 63 | 20 |
| Clonazepam | Clonazepam | 62 | 13 |
| Azithromycin | Azithromycin | 58 | 50 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 20 |
| Warfarin Sodium | Warfarin Sodium | 58 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 56 | 21 |
| Benazepril Hcl | Benazepril Hcl | 53 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 20 |
| Atenolol | Atenolol | 52 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 49 | 21 |
| Bupropion Hcl Sr | Bupropion Hcl | 47 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | 14 |
| Glimepiride | Glimepiride | 47 | 20 |
| Xarelto | Rivaroxaban | 47 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 34 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 17 |
| Memantine Hcl | Memantine Hcl | 44 | 12 |
| Mounjaro | Tirzepatide | 43 | 14 |
| Amoxicillin | Amoxicillin | 42 | 38 |
| Valsartan | Valsartan | 41 | 13 |
| Cephalexin | Cephalexin | 40 | 34 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 34 |
| Estradiol | Estradiol | 39 | 15 |
| Meclizine Hcl | Meclizine Hcl | 39 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 17 |
| Azelastine Hcl | Azelastine Hcl | 37 | 15 |
| Farxiga | Dapagliflozin Propanediol | 37 | 12 |
| Methocarbamol | Methocarbamol | 37 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 28 |
| Torsemide | Torsemide | 36 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | 15 |
| Sildenafil Citrate | Sildenafil Citrate | 34 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | 12 |
| Valacyclovir | Valacyclovir Hcl | 33 | 22 |
| Indapamide | Indapamide | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 31 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Jantoven | Warfarin Sodium | 28 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 18 |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 24 |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 12 |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Benzonatate | Benzonatate | 12 | 11 |
| Budesonide Dr | Budesonide | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $363.49 · 18 records | Abbott Laboratories | ABRYSVO, AREXVY, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, GARDASIL 9, INCEPTIV, INSPIRE, PREVNAR 20, PYRUKYND, SHINGRIX, VENASEAL, WaveWriter Alpha Prime 16, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error